Ongoing important trials
CIRCULATE-US — ctDNA-guided adjuvant chemotherapy (stage II–III colon)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase
- Phase II/III
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT05174169
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? After surgery, blood tumor DNA is being studied to help decide whether chemotherapy is needed.
Why promising? Aims to personalize adjuvant intensity using ctDNA MRD in a randomized design.
What is not proven? Primary results pending; not every ctDNA assay is equivalent.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase II/III; recruiting. Cross-read with Landmark DYNAMIC; no gold-star change.
Cancer / population: Colon — Rezeke evre II–III kolon
Intervention: ctDNA durumuna göre adjuvan KT stratejisi (protokol kolları)
Primary endpoint: Protokol tanımlı DFS / ctDNA dönüşüm uçları
Limitations: Sonuç yok; assay-spesifik.
Landmark Atlas links
Cross-links are informational only; this module does not award or change gold stars.